Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy
Medicinal Research Reviews · 2024-07 · 44 (4) · 1566-1595
DOI: 10.1002/med.22018 ↗At a glance
Übersichtsarbeit in Medicinal Research Reviews, published online on 2024-01-29. Written by Ying Hou and 4 co-authors. Institution: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China. Major MEDLINE topics: Reactive Oxygen Species, Lung Neoplasms, Carcinogenesis. Cited 36 times so far (Crossref); 206 references. Funded by: Science and Technology Development Fund of Macau SAR, Research Fund of University of Macau, Natural Science Foundation of Guangdong Province.
Abstract (original language)
Lung cancer is a major cause of morbidity and mortality. The specific pulmonary structure to directly connect with ambient air makes it more susceptible to damage from airborne toxins. External oxidative stimuli and endogenous reactive oxygen species (ROS) play a crucial role in promoting lung carcinogenesis and development. The biological properties of higher ROS levels in tumor cells than in normal cells make them more sensitive and vulnerable to ROS injury. Therefore, the strategy of targeting ROS has been proposed for cancer therapy for decades. However, it is embarrassing that countless attempts at ROS‐based therapies have had very limited success, and no FDA approval in the anticancer list was mechanistically based on ROS manipulation. Even compared with the untargetable proteins, such as transcription factors, ROS are more difficult to be targeted due to their chemical properties. Thus, the pleiotropic roles of ROS provide therapeutic potential for anticancer drug discovery, while a better dissection of the mechanistic action and signaling pathways is a prerequisite for future breakthroughs. This review discusses the critical roles of ROS in cancer carcinogenesis, ROS‐inspired signaling pathways, and ROS‐based treatment, exemplified by lung cancer. In particular, an eight considerations rule is proposed for ROS‐targeting strategies and drug design and development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China.
- Department of Clinical Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, China.
- Key Laboratory of Longevity and Aging-Related Diseases of Chinese Ministry of Education, Guangxi Key Laboratory of Research and Evaluation of Bioactive Molecules & College of Pharmacy, Guangxi Medical University, Nannin…
- Department of Pharmaceutical Sciences, University of Macau, Taipa, Macao, China.
- MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macao, China.
ORCID profiles: Xiuping Chen
Funding
- Science and Technology Development Fund of Macau SAR
- Research Fund of University of Macau
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
- MOE Frontiers Science Centre for Precision Oncology at University of Macau (FSCPO)
Cite
APA
Hou, Y., Wang, H., Wu, J., Guo, H., & Chen, X. (2024). Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy. Medicinal Research Reviews, 44(4), 1566-1595. https://doi.org/10.1002/med.22018
Vancouver
Hou Y, Wang H, Wu J, Guo H, Chen X. Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy. Medicinal Research Reviews. 2024;44(4):1566-1595. doi:10.1002/med.22018
BibTeX
@article{Hou2024,
author = {Hou, Ying and Wang, Heng and Wu, Jiarui and Guo, Hongwei and Chen, Xiuping},
title = {Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {4},
pages = {1566--1595},
doi = {10.1002/med.22018}
}
EUVIMED